1.75
-0.18 (-9.33%)
-0.18 (-9.33%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 168,943 |
|
|||||
| News | (1) | ||||||
| Day High | 1.96 | Low High |
|||||
| Day Low | 1.73 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Gemini Therapeutics Inc | GMTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.18 | -9.33% | 1.75 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.95 | 1.73 | 1.96 | 1.76 | 1.93 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,359 | 168,943 | $ 1.80 | $ 304,195 | - | 1.16 - 5.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:28:01 | 3 | $ 1.76 | USD |
Period:
Draw Mode:
Gemini Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 75.65M | 43.23M | 22.44M | $ - | $ - | -1.81 | -1.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 9.96k | 0.90% |
Gemini Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GMTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.55 | 2.12 | 1.25 | 1.96 | 373,257 | 0.20 | 12.9% |
| 1 Month | 1.63 | 2.12 | 1.25 | 1.80 | 160,228 | 0.12 | 7.36% |
| 3 Months | 1.45 | 2.12 | 1.20 | 1.64 | 177,937 | 0.30 | 20.69% |
| 6 Months | 1.68 | 2.12 | 1.16 | 1.51 | 244,135 | 0.07 | 4.17% |
| 1 Year | 4.14 | 5.48 | 1.16 | 2.71 | 474,355 | -2.39 | -57.73% |
| 3 Years | 12.15 | 19.085 | 1.16 | 4.66 | 436,334 | -10.40 | -85.6% |
| 5 Years | 12.15 | 19.085 | 1.16 | 4.66 | 436,334 | -10.40 | -85.6% |
Gemini Therapeutics Description
| Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. |